BETA
Your AI-Trained Oncology Knowledge Connection!
Machine Learning Approach May Predict Outcomes in RCC
A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.
An International Search for Lung Cancer Treatment Leads to Double Lung Transplant
The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.
Epcoritamab Demonstrates Complete Responses at 2 Years in R/R LBCL
Results from the EPCORE NHL-1 trial shared at the 2025 ASCO Annual Meeting found positive responses in patients with relapsed/refractory large B-cell lymphoma.
PFS, OS Numerically Improve Via IMNN-001 Combo in Epithelial Ovarian Cancer
Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.
Rechallenge With RET Inhibitors Shows Efficacy in Pretreated NSCLC
RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.
Six or More Cycles of Chemo Prolong Survival With Atezolizumab in ES-SCLC
The median OS was 18.5 months in those who received 6 or more cycles of induction chemotherapy vs 13.1 months in those who did not.
Pembrolizumab/Cisplatin and RT Enhance Responses in Unresectable Vulvar Cancer
For patients with unresectable vulvar cancer, an improved ORR was observed with pembrolizumab plus cisplatin and RT followed by maintenance pembrolizumab.
EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma
In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.
MagnetisMM-6 Data Suggest Safety, Manageability of Elranatamab Combo in NDMM
Results from part 1 dose level G of the MagnetisMM-6 trial found elranatamab, daratumumab, and lenalidomide to be safe and manageable in NDMM.
Ziftomenib Shows MRD-Negative Responses in Pretreated NPM1+ AML
The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.
No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma
Compared with nivolumab alone, nivolumab/relatlimab did not improve RFS in patients with resected stage III to IV melanoma.
Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC
A combination of BCG and mitomycin offers a comparable treatment option to BCG monotherapy for NMIBC, potentially lessening the impact of global BCG shortages.
Daratumumab Plus KRd May Be a New SOC Option in NDMM
Daratumumab plus KRd improved MRD-negativity and PFS vs KRd alone in patients with newly diagnosed multiple myeloma.
FDA OKs Darolutamide in Metastatic Castration-Sensitive Prostate Cancer
Results from the phase 3 ARANOTE trial demonstrated a statistically meaningful improvement to rPFS with darolutamide vs placebo.
CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer
The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.
IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer Subgroup
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Subcutaneous Daratumumab Combo Sustains MRD-Negative Status in NDMM
Results from the PERSEUS trial support daratumumab plus bortezomib, lenalidomide, and dexamethasone as a standard of care in transplant-eligible NDMM.
Niraparib Plus Abiraterone/Prednisone Extends rPFS in HRR-Altered mCSPC
Niraparib plus abiraterone acetate and prednisone significantly reduced the risk of symptomatic progression in patients with BRCA-mutated metastatic castration-sensitive prostate cancer.
Ziftomenib Earns FDA Priority Review for R/R NPM1-Mutant AML
The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.
Significant OS Benefit Observed With NAT Nivolumab/Chemo in Resectable NSCLC
Results from CheckMate-816 could be practice-changing after an OS improvement was noted with NAT nivolumab plus chemotherapy in resectable NSCLC.
Benmelstobart With/Without Anlotinib Is Effective Consolidation Therapy in NSCLC
Benmelstobart-based regimens provide clinically meaningful PFS benefits as consolidation therapy for unresectable stage III non–small cell lung cancer.
SCRT/Chemo Produce Positive Responses in Locally Advanced Rectal Cancer
Results from the ShorTrip trial found that SCRT plus chemotherapy regimens showed promising efficacy for patients with locally advanced rectal cancer.
Nivolumab Extends EFS Across Resectable NSCLC Subgroups
Efficacy and biomarker analyses from CheckMate-77T support perioperative nivolumab as an effective option in resectable NSCLC.
Neoadjuvant Osimertinib Enhances Responses in Resectable EGFR-Mutated NSCLC
An efficacy advantage with osimertinib-containing regimens was consistent across predefined patient subgroups in those with EGFR-mutant NSCLC.
Less Inflammatory Diets Associated with Improved OS in Stage III Colon Cancer
Data suggest that anti-inflammatory diets and regular physical activity are associated with improved overall survival in patients with stage III resected colon cancer.
Disitamab Vedotin/Toripalimab/Trastuzumab Yield Responses in G/GEJ Cancer
Disitamab vedotin, toripalimab, and trastuzumab demonstrated superior response rates and efficacy in HER2-overexpressing metastatic gastric cancers.
Relacorilant and Nab-Paclitaxel Significantly Extend PFS in Ovarian Cancer
Data from the ROSELLA trial may support relacorilant plus nab-paclitaxel as a new standard in this ovarian cancer population.
Daratumumab Combo Improves Outcomes in Transplant-Ineligible NDMM Subgroups
Subgroup data from the CEPHEUS trial reinforce daratumumab plus bortezomib, lenalidomide, and dexamethasone as a standard of care in this population.
EBC-129 Shows Early Activity in Advanced Pancreatic Ductal Adenocarcinoma
EBC-129 was well tolerated, with a safety profile consistent with other MMAE-based ADCs in patients with PDAC and other solid tumors.
Pembrolizumab/Chemoradiation Prolongs Survival in Advanced Cervical Cancer
Data from KEYNOTE-A18 support pembrolizumab plus concurrent chemoradiotherapy as a standard of care in this cervical cancer population.
